EGFR and non-small cell lung carcinoma: Compared to patients with low baseline serum EGFR expression (≤ 16.0), patients of NSCLC with high serum EGFR (> 16.0) had 2.9 times higher risk of mortality and 1.7 times higher risk of disease progression.